Abstract-Experimental and population-based studies indicate that female gender and estrogens protect the cardiovascular system against aldosterone-induced injury. Understanding the function of estrogens in heart disease requires more precise information on the role of both estrogen receptor (ER) subtypes, ER␣ and ER␤. Therefore, we determined whether selective activation of ER␣ or of ER␤ would confer redundant, specific, or opposing effects on cardiovascular remodeling in aldosterone salt-treated rats. The ER␣ agonist 16␣-LE2, the ER␤ agonist 8␤-VE2, and the nonselective estrogen receptor agonist 17␤-estradiol lowered elevated blood pressure, cardiac mass, and cardiac myocyte cross-sectional areas, as well as increased perivascular collagen accumulation and vascular osteopontin expression in ovariectomized rats receiving chronic aldosterone infusion plus a high-salt diet for 8 weeks. Uterus atrophy was prevented by 16␣-LE2 and 17␤-estradiol but not by 8␤-VE2. Cardiac proteome analyses by 2D gel electrophoresis, mass spectrometry, and peptide sequencing identified specific subsets of proteins involved in cardiac contractility, energy metabolism, cellular stress response and extracellular matrix formation that were regulated in opposite directions by aldosterone salt treatment and by different estrogen receptor agonists. We conclude that activation of either ER␣ or ER␤ protects the cardiovascular system against the detrimental effects of aldosterone salt treatment and confers redundant, as well as specific, effects on cardiac protein expression. Nonfeminizing ER␤ agonists such as 8␤-VE2 have a therapeutic potential in the treatment of hypertensive heart disease. (Hypertension. 2007;50:432-438.)
strogens and mineralocorticoids act on the cardiovascular system via specific cognate receptors, the mineralocorticoid receptor (MR), and 2 distinct estrogen receptor (ER) subtypes, ER␣ and ER␤. Both ER␣ and ER␤, as well as the MR, are related members of the nuclear hormone receptor family, which play important roles and may functionally interact in blood pressure maintenance and in the adaptive response of cardiac muscle toward increased workload and injury.
Ligand-dependent activation of the MR by aldosterone promotes sodium and water reabsorption via the kidney and the colonic mucosa. However, elevated aldosterone serum levels in combination with a high-salt diet or altered MR expression promote hypertension and cardiac remodeling including perivascular inflammation, cardiac fibrosis, and cardiac hypertrophy. [1] [2] [3] [4] [5] Activation of the MR in patients with chronic heart failure represents part of a maladaptive response that triggers a vicious cycle after cardiac injury. In support of this concept, MR antagonists such as spironolactone or eplerenone have been shown to ameliorate the symptoms and to prolong survival in patients with advanced chronic heart failure. 6 -8 The observation that serum aldosterone levels correlate positively with left ventricular hypertrophy and left ventricular mass index in women but not in men suggests important interactions between estrogen and MR signaling. 9, 10 Recently we were able to support this concept by showing that the nonselective ER agonist 17␤-estradiol protects aldosterone salt-treated (AST) rats from classical features of MR-mediated cardiovascular injury. 11 The observation that uterus atrophy occurred in ER␣-but not in ER␤-deficient mice provided the first evidence for different physiological functions of ER␣ and ER␤. 12 However, both ER subtypes are also capable of mediating redundant functions in augmenting vascular NO generation. 13, 14 Therefore, a more accurate understanding of how estrogens protect against the development of cardiovascular disease depends directly on a more detailed knowledge on specific, redundant, and eventually also opposing functions of both ER subtypes. 15, 16 The divergent role of both ER subtypes in different tissues promoted the development of potent, isotype-selective agonists for ER␣ and for ER␤, such as the ER␣ agonist 16␣-LE2 and the ER␤ agonist 8␤-VE2. These ligands were synthesized based on discrete differences in the 3D structure of the ligand-binding pocket of ER␣ and ER␤ and confer biological effects that are in direct line with the function of ER␣ and ER␤ in reproductive organs. 17, 18 Herein, we report that selective activation of either ER␣ or of ER␤ by isotypespecific agonists protects the rodent heart against aldosterone salt-treatment-induced hypertension, vascular inflammation, and cardiac hypertrophy. We also report on the identification of proteins that are differentially expressed in the heart in response to the activation of the MR, ER␣, and ER␤.
Methods

Animal Treatment
Sixty female Wistar rats obtained from IFFA CREDO (Lyon, France) at the age of 12 weeks were randomly divided into 6 groups: group 1, sham ovariectomy, placebo injections; group 2, ovariectomy, osmotic minipump containing carrier solution, placebo injection. Animals in groups 3 to 6 were ovariectomized and uninephrectomized and received continuous aldosterone infusion via osmotic minipumps (Alzet model 2004; 0.75 g/h) for 8 weeks together with a high-salt diet (1% NaCl added to tap) plus daily subcutaneous injections of the following: group 3, placebo; group 4, 17␤-estradiol (2 g/kg per day); group 5, 16␣-LE2 (selective ER␣ agonist, 30 g/kg per day); and group 6, 8␤-VE2 (selective ER␤ agonist, 100 g/kg per day). For information on the binding affinities of 16␣-LE2 and 8␤-VE2 to steroid hormone receptors other than ER␣ and ER␤, please see the online supplemental data (available at http://hyper. ahajournals.org). Treatment with aldosterone plus salt and with different estrogens was initiated immediately after ovariectomy and continued for 12 weeks. The dose of 17␤-estradiol was chosen to achieve physiological serum estradiol levels, and 16␣-LE2 and 8␤-VE2 were injected in pharmacological dosages at which both ligands are still ER subtype selective. 18 All of the protocols were reviewed and accepted by the local ethics committee and performed in accordance with the current National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Hemodynamic Measurements
Invasive hemodynamic measurements were performed as described before under light isoflurane anesthesia and spontaneous respiration. 19 Body weight, heart weight, uterus weight, and kidney weight were determined after hemodynamic analysis. Relative heart weight was calculated from absolute heart weight and tibia length. 20 Estradiol and angiotensin II serum levels were determined by radio immunoassays according to the manufacturer's instructions (estradiol: DPC-Biermann; angiotensin II: Peninsula).
Morphometry
Perivascular collagen accumulation was quantified in each animal around Ն6 individual coronary arteries in 3 nonconsecutive sections (total measurements: 972 arteries), and cardiac myocyte crosssectional areas were determined in all of the rats (total: 4320 myocytes) according to published protocols. 11 Media cross-sectional areas of the thoracic aorta were calculated by manual tracing of the internal elastic lamina and the external limit of the media using the Image J software in Ն3 independent sections from Ն3 specimens from each animal (total measurements: 175 aortas). 11
Immunohistochemistry
Aortic cross-sections were stained for osteopontin according to published protocols. 11 Each slide was compared with an adjacent section in which primary antibodies were omitted. Immunostainings for osteopontin were quantified using the Scion software. At least 3 sections per specimen with 3 fields of view per section were analyzed in Ն4 animals per group (total measurements: 216 sections).
2D Gel Electrophoresis and Protein Analysis
Protein extracts from the left ventricle were subjected to 2D gel electrophoresis, and image acquisition and data analysis were performed following general Amersham protocols. Three extracts that were differentially labeled with fluorescent dyes containing Cy1, Cy2, or Cy3 were loaded and analyzed simultaneously on a single gel (1: internal standard, Cy2; 2: ovariectomized rat [ovx] ϪASTϪplacebo, Cy3; and 3: one of the following: ovxϪASTϪ17␤-estradiol, ovxϪASTϪ16␣-LE2, or ovxϪASTϪ8␤-VE2ϭCy5). Protein expression patterns were determined in 3 animals per group, and spot intensities were compared with the internal reference group (ovxϪASTϪplacebo) in which spot intensity was set to Ϯ1. Protein spots were excised from preparative gels, and peptide mapping by matrix assisted laser desorption ionization-time of flight was performed on a TofSpec 2E instrument. Peptide sequencing was carried out on an Esquire 3000 ion trap mass analyzer (Bruker Daltonics). Peptide mass fingerprint and sequence data were subjected to database search (SwissProt, Swiss Institute of Bioinformatics) using the Mascot search engine (Matrix Science LTD). A more detailed technical description is available in the online supplemental data.
Statistics
Results indicate meanϮSEM. Multigroup comparisons were done by 1-way ANOVA followed by Student-Newman-Keuls posthoc allpairwise testing using the SigmaStat 2.03 software, and PϽ0.05 was considered significant. 2D gel electrophoresis data were analyzed by ANOVA and Student t test using DeCyder Software (Amersham), and PϽ0.01 was considered significant.
Results
Cardiac Hypertrophy and Hemodynamic Analysis
Cardiac mass and blood pressure were increased in ovx animals receiving chronic aldosterone infusion plus a highsalt diet (AST rats) compared with estrogen-depleted rats receiving a normal diet together with osmotic minipumps containing only carrier solution ( Figure 1A and Table 1 ). Systolic and mean blood pressure levels, as well as relative heart weight, were lower in AST rats treated with the ER␣ agonist 16␣-LE2, the ER␤ agonist 8␤-VE2, or the nonselective ER agonist 17␤-estradiol compared with AST rats receiving placebo injections. Assessment of cardiac hypertrophy on the single cardiac myocyte level revealed a doubling of cardiac myocyte cross-sectional area in AST rats that was abrogated by treatment with the ER␣ agonist 16␣-LE2, the ER␤ agonist 8␤-VE2, and the nonselective ER agonist 17␤-estradiol (Table 1 and Figure 1A and 1B).
Global Measurements
Body mass was increased in ovariectomized compared with intact rats and not altered by aldosterone-salt treatment ( Table  1 ). The selective ER␣ agonist 16␣-LE2 and the nonselective ER agonist 17␤-estradiol but not the ER␤ agonist 8␤-VE2 attenuated the adipose phenotype of estrogen-depleted rats. Uterine weight and serum estradiol levels were decreased in ovx rats. Uterus atrophy was prevented by 17␤-estradiol and by 16␣-LE2 but not by the ER␤ agonist 8␤-VE2. Serum estradiol levels were lower in ovariectomized compared with sham-operated rats and returned to physiological levels in animals receiving injections with 17␤-estradiol. Serum an-giotensin II levels were suppressed to a comparable extent among all of the animals receiving AST treatment (Table 1) .
Vascular Remodeling and Gene Expression
Chronic aldosterone-salt treatment resulted in aortic media thickening ( Figure 2A and 2B), perivascular fibrosis of coronary arteries ( Figure 2C and 2D), and higher osteopontin expression levels in the aortic media compared with shamoperated rats or ovxs ( Figure 2E and 2F). Treatment of AST rats with the ER␣ agonist 16␣-LE2, the ER␤ agonist 8␤-VE2, or 17␤-estradiol attenuated aortic media hypertrophy, fibrosis, and osteopontin expression (Figure 2A through 2F). Cardiac ER␣ and ER␤ protein expression and MR mRNA levels were not different among all of the treatment groups (see online supplemental data).
Cardiac Proteome Analyses
On average, Ϸ1400 individual protein spots were detected by 2D gel electrophoresis of unfractionated cardiac extracts ( Figure 3A) . Treatment of AST rats with the ER␣ agonist 16␣-LE2, the ER␤ agonist 8␤-VE2, or the nonselective ER agonist 17␤-estradiol altered the expression levels of specific proteins involved in cardiac contractility (␣-myosin heavy chain [␣-MHC]), signal transduction (neurabin II), energy metabolism (ATP-synthase ␣-chain), cellular stress response, and extracellular matrix formation (fibromodulin; Table 2 and Figure 3B ), whereas lactate dehydrogenase-2, malate dehydrogenase, cardiac ␣-actin, and reduced nicotinamideadenine dinucleotide-ubiquinone oxidoreductase expression were not significantly responsive to estrogen treatment. Western blotting experiments confirmed the observation that 17␤-estradiol, 16␣-LE2, and 8␤-VE2 attenuated increased cardiac neurabin II expression in AST rats (see supplemental data).
Discussion
The major findings of this study can be summarized as follows: First, activation of either ER␣ or of ER␤ protects female AST rats against hypertension, cardiac hypertrophy, vascular fibrosis, and increased osteopontin expression. Second, the efficacy of ER␣ to modulate blood pressure varies substantially among different animal models. Third, aldosterone-salt treatment confers specific alterations on the cardiac proteome that are partially and differentially reversed by treatment with ER␣ or ER␤ selective agonists.
Elevated aldosterone serum levels together with a high-salt diet promote hypertension and vascular dysfunction in humans and in animal models of human heart disease. 9, 21 Although ER␣ and ER␤ augment local NO bioavailability, which is impaired by excess MR activation, hypertension has been reported only in ER␤ but not in ER␣ knockout mice. 11, 15, 16, 20, 22, 23 Along the same line, the ER␣ agonist 16␣-LE2 failed to decrease elevated blood pressure in spontaneously hypertensive rats. 19 These findings could be taken as good evidence against a general function of ER␣ in blood pressure maintenance. However, decreased blood pressure levels in AST rats receiving the ER␣ agonist 16␣-LE2 are in contrast to such a general hypothesis. Instead, it seems that the functional role of ER␣ in blood pressure maintenance presents differently in dependence of the cause or the model of hypertension. In particular, the suppression of angiotensin II levels in AST rats might confer a permissive effect on the ER␣ agonist 16␣-LE2 to modulate blood pressure, because an identical dose of the same ligand failed to lower elevated blood pressure in female spontaneous hypertensive rats in which serum angiotensin II was much higher than in AST rats (P. Arias-Loza, unpublished data, 2006). Lower blood pressure levels among AST rats receiving the ER␤ agonist 8␤-VE2 are in direct line with elevated blood pressure in ER␤ knockout mice and provide novel and independent evidence in support of ER␤ as an important regulatory factor of blood pressure maintenance. 23 Chronic aldosterone-salt treatment promoted extensive vascular remodeling in AST rats, which was linked to increased vascular osteopontin expression. 11, 21 Of note, os- Figure 1 . A, Cardiac cross-sections (hematoxylin/eosin) illustrate increased cardiac mass in AST rats (ovx AST placebo) compared with sham-operated rats or ovxs that was attenuated by cotreatment with the ER␣ agonist 16␣-LE2, the ER␤ agonist 8␤-VE2, and the nonselective ER agonist 17␤-estradiol (E2). B, Enlarged cardiac myocyte cross-sectional areas in estrogendepleted AST rats (ovx AST placebo) decreased on treatment with the ER␣ agonist 16␣-LE2, the ER␤ agonist 8␤-VE2, or the nonselective ER agonist 17␤-estradiol (hematoxylin staining).
teopontin not only serves as a marker of vascular inflammation but also plays a functional role in vascular remodeling, because osteopontin-deficient mice are resistant to aldosterone-induced cardiac fibrosis. 24 Interestingly, 17␤-estradiol has been shown to directly attenuate osteopontin expression in vascular smooth muscle cells. 25 Together, these data suggest that the protective functions of 16␣-LE2, 8␤-VE2, and 17␤-estradiol on vascular remodeling and on vascular osteopontin expression are functionally linked processes.
Cardiac hypertrophy is a common consequence of hypertension and an independent predictor of cardiovascular mortality. 26 Both ER subtypes have been reported to attenuate cardiac hypertrophy in genetic mouse models or in pharmacological studies. 19, 27, 28 In contrast to previous studies in spontaneous hypertensive rats, which did not reveal a blood pressure-lowering effect of 16␣-LE2, the antihypertrophic effects of 16␣-LE2 (and of 8␤-VE2) in AST rats are most likely explained by lower blood pressure levels, though we cannot formally rule out the presence of additional and direct hormone effects on the myocardium. Smaller cardiac myocyte cross-sectional areas in AST rats receiving ER␣ or ER␤ selective agonist treatment support this interpretation and indicate that beneficial estrogen effects can be achieved by an ER␤ ligand that does not stimulate uterine growth. Although cardiac hypertrophy was attenuated by ER␣ and ER␤ selective agonists, only the activation of ER␣ by either 16␣-LE2 or by 17␤-estradiol and, of note, not the activation of ER␤ by 8␤-VE2, prevented the downregulation of cardiac ␣-MHC expression in ovariectomized AST rats. These observations support the hypothesis that estrogens attenuate the downregulation of cardiac ␣-MHC expression, which was repeatedly observed in estrogen-depleted rats via activation of the ER␣ but not of the ER␤ receptor. 19, 29 In contrast to ␣-MHC, activation of ER␣ and of ER␤ attenuated increased expression levels of the scaffolding protein neurabin II, which targets protein phosphatase I to the actin cytoskeleton in AST rats. 30, 31 Enhanced cardiac protein phosphatase I targeting could be functionally relevant, because transgenic mice overexpressing protein phosphatase I develop a dilative cardiomyopathy-like syndrome. 32 In contrast to ␣-MHC and neurabin II, only by the ER␤ agonist 8␤-VE2 and 17␤-estradiol but, of note, not the ER␣ agonist 16␣-LE2 prevented the downregulation of the ATP synthase ␣-chain and of fibromodulin in AST rats. Fibromodulin expression and function have so far not been studied in the heart despite a single report showing increased expression of this protein in cardiac myxoma. 33 Nevertheless, it is conceivable that fibromodulin might play a role in the maturation of the cardiac collagen matrix, because fibromodulin-deficient mice exhibit extreme tendon weakness and an excess of immature collagen fibrils resembling Ehlers-Danlos syndrome. 34 Finally, a number of proteins involved in cardiac metabolism, stress response, and cellular and sarcomere structure, including lactate dehydrogenase-2, malate dehydrogenase, lactate dehydrogenase ␤-chain, cardiac ␣-actin, and reduced nicotinamide-adenine dinucleotide-ubiquinone oxidoreductase, showed differential expression patterns in AST rats that were not responsive to estrogen treatment and, hence, unlikely to affect the cardiac phenotype of estrogen-treated AST rats.
Perspectives
Clinical and experimental data suggest important interactions between mineralocorticoid and ER function in cardiac and Table 2 . B, Representative photomicrographs of protein spots that show differential intensity among rats from different treatment groups. The downregulation of fibromodulin in AST rats was attenuated by 17␤-estradiol (E2) and the ER␤ agonist 8␤-VE2. Increased neurabin II expression in AST rats was attenuated by 17␤-estradiol, 16␣-LE2, and 8␤-VE2. Decreased ATPsynthase ␣-chain expression in AST rats was restored by 17␤-estradiol and by 8␤-VE2 but remained low in AST rats receiving the ER␣ agonist 16␣-LE2 (nϭ3 animals per group).
vascular injury. This report shows that both ER subtypes possess redundant functions in protecting the cardiovascular system against the detrimental effects of aldosterone-salt treatment. Nonfeminizing ER␤ agonists have a therapeutic potential in treating hypertensive heart disease that deserves further evaluation. 
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2D-DIGE Analysis
An internal standard was generated by pooling equal aliquots from each of the two extracts to be run on one gel. Protein extracts and the internal standard were labeled prior to electrophoresis with CyDyes™. Each solid dye was reconstituted in anhydrous dimethylformamide (DMF) and adjusted to a concentration of 1 nmol/µl. Just prior to the labeling reaction the reconstituted dye was diluted with DMF to obtain a final concentration of 400 pmol/µl. For one gel, 50 µg of each protein sample and the internal standard, were mixed with 1 µl of Cy2, Cy3 or Cy5 (400 pmol), 
Image Acquisition and Analysis
Image acquisition was performed using the Typhoon™ 9400 imager (Amersham Biosciences).
Cy2 images were scanned using a 488 nm blue laser and an emission filter of 520 nm BP (band pass) 40. Cy3 images were recorded using a 532 nm green laser, 580 nm BP 30, and Cy5 using a 633 nm red laser, 670 nm BP 30. All gels were scanned at 100 µm resolution. Gel analysis was performed using DeCyder™ V 5.0 (Amersham Biosciences). Protein spot co-detection and quantification was carried out using the DeCyder software module. The estimated number of spots for each co-detection procedure was set to 2500. The data from the three independent gels of each experiment were imported into the DeCyder BVA module for inter-gel analysis, including inter-gel matching followed by statistical analysis of protein abundance between samples. For inter-gel matching, one internal standard image was defined as the master and the two other internal standard images were matched with the master gel. Data were analyzed by applying two statistical tests (Student's t-test and one-way ANOVA). Proteins with a t-test value < 0.01 and an average ratio exceeding +/-2 were considered significant. 
Preparative Gels
Mass Spectrometry
Protein spots excised from preparative gels were cleaned with water, shrunk with acetonitrile and dried before overnight digestion at 37C° with 10 µl of enzyme solution containing 20 ng/µl trypsin (Roche, sequencing grade). Peptides were extracted by increasing concentrations of acetonitrile containing 1 % acetic acid (10 %, 50 %, 80 %, subsequently) and desalted with µC18 ZipTips (Millipore, Bedford, MA, USA). Peptide mapping by MALDI-TOF was carried out on a TofSpec 2E instrument (Waters/Micromass, Manchester, UK) using 0.5 µl of peptide mixture and 0.5 µl of 4-hydroxy-α-cyano cinnamic acid (10 mg/ml in 50% acetonitrile and 0.05% trifluoro acetic acid) per sample well. Peptide sequencing was performed on an Esquire 3000 ion trap mass analyzer (Bruker Daltonics, Bremen, Germany) coupled to an Ultimate Cardiac MR and 18s (standard) mRNA expression levels were quantified by real-time PCR of total heart RNA isolated with TRIzol (Life Technologies, USA). 1µg of RNA was reverse transcribed using AMV reverse transcriptase (Promega) and MR mRNA expression was quantified using an ABI Prism iCycler detection system. The following PCR primers and probe for rat MR were designed according to published rat MR mRNA sequences (M36074) and obtained from Applied Biosystems: rMR forward primer: 5´-GACGTGGATTTGCAAGGCCT GAG-3´; rMR reverse primer: 5´-TTTCATCCAGAGGAACGGGAACATG-3´; probe: 5´-TAAAGGACTCTTCCCTCTCCACTCCCAGCGCTT-3´. Cardiac MR mRNA expression is shown in figure S1 .
Part 3 Pharmacological profile of 16α-LE2 and 8β-VE2 on different nuclear hormone receptors
Receptor binding was tested in steroid receptor containing cytosolic fractions of baculovirus infected SF-9 insect cells producing the human steroid hormone receptors: estrogen receptor α (hERα), estrogen receptor β (hERβ), progestogen receptor (hPR), glucocorticoid receptor (hGR), androgen receptor (hAR) or mineralocorticoid receptor (hMR) as shown in table S1. 
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Abbreviations: aldo: aldosterone; dexa: dexamethasone; prog: progesterone; RBA: relative binding affinity; n.c.: no competition; n: number of independent measurements. 
